Amyris price target lowered to $1.50 from $2 at Piper Sandler

Piper Sandler lowered the firm’s price target on Amyris to $1.50 from $2 and keeps a Neutral rating on the shares post the Q4 report. Challenges are persisting for Amyris with revenue and the 2023 outlook coming in far weaker than anticipated, the analyst tells investors in a research note. However, the firm believes management is starting to present more realistic expectations.